Screening for Cognitive Dysfunction Using the Rowland Universal Dementia Assessment Scale in Adults With Sickle Cell Disease
Stéphanie Forté(University Health Network), Kevin H.M. Kuo(University Health Network), Mireille Fortier-St-Pierre(Centre Hospitalier de l’Université de Montréal), Sébastien Béland(Université de Montréal), Maryline Couette(Inserm), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Nafanta Fadiga(University Health Network), Richard Ward(University of Tennessee Health Science Center), Mathias Castonguay(Centre Hospitalier de l’Université de Montréal), Florence Blais(Centre Hospitalier de l’Université de Montréal), Mélanie Cohn(Johnson Foundation)
Cited by 14
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Online haemodiafiltration: definition, dose quantification and safety revisited
|Nephrology Dialysis Transplantation|2013|256
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162